Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

IMPORTANCE: Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor taken once daily, is approved in the United States for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and allows for treatment without chemotherapy. Extended treatment with ibrutinib has demonstrated incr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Oncol
Hauptverfasser: O’Brien, Susan M., Jaglowski, Samantha, Byrd, John C., Bannerji, Rajat, Blum, Kristie A., Fox, Christopher P., Furman, Richard R., Hillmen, Peter, Kipps, Thomas J., Montillo, Marco, Sharman, Jeff, Suzuki, Sam, James, Danelle F., Chu, Alvina D., Coutre, Steven E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2018
Schlagworte:
Brief Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885180/
https://ncbi.nlm.nih.gov/pubmed/29470582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5604
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge